Showing 2221-2230 of 3017 results for "".
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem
- Medivir’s Remetinostat Shows Promise for SCChttps://practicaldermatology.com/news/medivirs-remetinostat-shows-promise-for-scc/2460807/Topical remetinostat gel performed well in a small investigator-initiated phase II clinical study of patients with squamous cell carcinoma. Four patients with five cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumors, including
- Curcumin Nanoparticles May Be Viable Adjuvant for Sunscreenhttps://practicaldermatology.com/news/curcumin-nanoparticles-may-be-viable-adjuvant-for-sunscreen/2460803/Curcumin may be a viable photoprotective adjuvant when delivered through nanoparticles, according to research published by a collaborative team from the George Washington University (GW) School of Medicine and Health Sciences (SMHS) Department of Dermatology and Albert Einstein College of Medicin
- Breaking Business News: Cynosure to Acquire MyEllevate Surgical Suture Systemhttps://practicaldermatology.com/news/breaking-business-news-cynosure-to-acquire-myellevate-surgical-suture-system/2460791/Cynosure is acquiring the MyEllevate Surgical Suture System, which allows practitioners to place a suture support system without incisions. MyEllevate, performed with the ICLED light-guided suture system, is the first and only patented light-guided technology for use in soft tissue
- FDA Nod for Modifications to Soliton's Resonic Devicehttps://practicaldermatology.com/news/fda-nod-for-modifications-to-solitons-tattoo-removal-device/2460790/The U.S. Food and Drug Administration granted Soliton, Inc. 510(k) for modifications to its RESONIC device. The RESONIC device utilizes the RAP technology to deliver safe and effective tattoo removal and cellulite treatment and now includes an autoloading cartridge and an
- New York City's Mount Sinai Launches Melanoma and Skin Cancer Centerhttps://practicaldermatology.com/news/new-york-citys-mount-sinai-launches-melanoma-and-skin-cancer-center/2460777/Mount Sinai received a second $10 million gift from the Waldman Family to open the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai. Housed within the Kimberly and Eric J. Waldman Department of Dermatology at the May
- Burt's Bees Nature-Based Ingredients Protect Against Evolving Skincare Challengeshttps://practicaldermatology.com/news/burts-bees-nature-based-ingredients-protect-against-evolving-skincare-challenges/2460772/Burt's Bees bakuchiol bests retinol when it comes to promoting expression of certain anti-aging genes, according to a poster presented at the 2021 American Academy of Dermatology Virtual Meeting Experience. And other new research supports the moisturization and skin barrier benefits
- Skin Bleaching for a Lighter Complexion Carries Serious Riskshttps://practicaldermatology.com/news/skin-bleaching-for-a-lighter-complexion-carries-serious-risks/2460769/Despite the potential dangers of skin bleaching products, the global market for skin lighteners last year was estimated at $8.6 billion and is projected to reach $12.3 billion by 2027. “The cultural beliefs that promote the practice of skin bleaching date back centuries
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- UCB’s Bimekizumab Outplays the Competition in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ucbs-bimekizumab-outplays-the-competition-in-two-phase-3-psoriasis-trials/2460764/UCB’s Bimekizumab almost entirely cleared moderate to severe psoriasis in more than 60 percent of the patients who took part in two Phase 3 clinical trials. Given via injection under the skin, Bimekizumab is a monoclonal antibody and the first to block both Interleukin 17A and Int